NCT02617134

Immunotherapy With Chimeric Antigen Receptor-Modified T Cells for MUC1 Positive Advanced Refractory Solid Tumor

Study Summary

The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with MUC1 positive relapsed or refractory solid tumor.

Want to learn more about this trial?

Request More Info

Interventions

anti-MUC1 CAR-T cellsBIOLOGICAL
No description available.

Study Locations

FacilityCityStateCountry
PersonGen Biomedicine (Suzhou) Co., Ltd.SuzhouJiangsuChina

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026